Comprehensive analysis of haemostatic profile depending on clinicopathological determinants in breast cancer patients.

about

Comprehensive analysis of haemostatic profile depending on clinicopathological determinants in breast cancer patients.

Item

http://www.wikidata.org/entity/Q54939232

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Comprehensive analysis of haem ...... nts in breast cancer patients.

@en

Comprehensive analysis of haem ...... nts in breast cancer patients.

@nl

type

Item

label

Comprehensive analysis of haem ...... nts in breast cancer patients.

@en

Comprehensive analysis of haem ...... nts in breast cancer patients.

@nl

prefLabel

Comprehensive analysis of haem ...... nts in breast cancer patients.

@en

Comprehensive analysis of haem ...... nts in breast cancer patients.

@nl

P1476

Comprehensive analysis of haem ...... ants in breast cancer patients

@en

P2093

Alen Brkic

http://www.w3.org/2001/XMLSchema#string

Barbara Góralczyk

http://www.w3.org/2001/XMLSchema#string

Barbara Ruszkowska-Ciastek

http://www.w3.org/2001/XMLSchema#string

Danuta Rość

http://www.w3.org/2001/XMLSchema#string

Elżbieta Zarychta

http://www.w3.org/2001/XMLSchema#string

Kornel Bielawski

http://www.w3.org/2001/XMLSchema#string

Piotr Rhone

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Platelets, coagulation and fibrinolysis in breast cancer progression

Activation of blood coagulation in cancer: implications for tumour progression

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.

TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.

Increased coagulation activity and genetic polymorphisms in the F5, F10 and EPCR genes are associated with breast cancer: a case-control study

Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer

Tissue factor-expressing tumor cells can bind to immobilized recombinant tissue factor pathway inhibitor under static and shear conditions in vitro

Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.

P31

scholarly article

P356

10.1042/BSR20171657

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Krzysztof Roszkowski

P577

2018-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29475895

http://www.w3.org/2001/XMLSchema#string

P932

5874264

http://www.w3.org/2001/XMLSchema#string